Kennedy Capital Management LLC Boosts Stock Position in Accolade, Inc. (NASDAQ:ACCD)

Kennedy Capital Management LLC raised its holdings in Accolade, Inc. (NASDAQ:ACCD - Free Report) by 40.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,065,757 shares of the company's stock after acquiring an additional 309,201 shares during the quarter. Kennedy Capital Management LLC owned about 1.31% of Accolade worth $3,645,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ACCD. Pallas Capital Advisors LLC bought a new position in shares of Accolade during the fourth quarter worth $38,000. Wolverine Trading LLC bought a new stake in Accolade during the 3rd quarter worth about $51,000. Pilgrim Partners Asia Pte Ltd acquired a new position in Accolade during the fourth quarter valued at approximately $54,000. RPO LLC bought a new position in shares of Accolade in the fourth quarter valued at $57,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in shares of Accolade by 49.9% in the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 17,804 shares of the company's stock valued at $61,000 after acquiring an additional 5,929 shares during the period. 84.99% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ACCD. Piper Sandler downgraded Accolade from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Stephens restated an "equal weight" rating and set a $7.03 target price on shares of Accolade in a research note on Wednesday, February 12th. Raymond James reaffirmed a "market perform" rating on shares of Accolade in a report on Thursday, January 9th. Stifel Nicolaus reaffirmed a "hold" rating and issued a $7.03 target price (down previously from $8.00) on shares of Accolade in a report on Thursday, January 9th. Finally, Canaccord Genuity Group reaffirmed a "hold" rating on shares of Accolade in a research note on Wednesday, January 8th. Thirteen investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $6.51.

Accolade Price Performance

Shares of ACCD remained flat at $7.02 during trading hours on Friday. The stock has a market capitalization of $575.59 million, a P/E ratio of -3.12 and a beta of 2.10. Accolade, Inc. has a 1 year low of $3.08 and a 1 year high of $9.67. The business's 50-day simple moving average is $6.97 and its 200-day simple moving average is $5.28. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.